Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients

NCT01895335 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

1001

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: Teriflunomide

Sponsor

Sanofi